The company's strong cash position gives investors confidence in the gene-editing stock.

The biotech startup Inscripta is attempting to “democratize” CRISPR by offering it to select researchers at no cost, according to Fortune. Here are four things to know about the startup’s business ...

Last year’s federal agency layoffs, grant discontinuations, and university funding cuts led to numerous warnings of the disastrous impact on U.S. science research. Gretchen Goldman, PhD, from the ...

The benefits of CAR-T therapies, which have been used to treat 27,000 patients, outweigh the risks that these therapies pose to patients, Peter Marks, director of US Food and Drug Administration (FDA) ...

Trace the timeline of CRISPR-Cas9 from its 2012 discovery to the latest AI-driven advancements and "N-of-1" clinical therapies.